NCT07354724Phase 1, phase 2Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease

Study sponsor: Denali Therapeutics Inc. · DNLI

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-08Estimated
Enrollment · participants32Estimated
Source updated2026-11-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.